NOTCH1 and B-cell chronic lymphocytic leukemia: Recently, Pagliaro L. et al. investigated a new treatment strategy that combines Notch inhibition using the SERCA inhibitor CAD204520 together with the first-line treatment Venetoclax, and ibrutinib (EMA and FDA-approved), mainly in Notch1-mutated CLL patients [129].